Form 4: Fractyl Health Executive Jay David Caplan Executes Stock Transactions Under 10b5-1 Plan

Jay David Caplan, President and Chief Product Officer of Fractyl Health, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Jay David Caplan, President and Chief Product Officer of Fractyl Health, engaged in several transactions involving the company's common stock.
• On January 30, 2025, Caplan exercised options for 21,472 shares at $1.70 per share and then sold the same number of shares at a weighted average price of $1.9468 per share.
• On January 31, 2025, Caplan exercised options for 22,346 shares at $1.70 per share and then sold the same number of shares at a weighted average price of $1.8108 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 13, 2024.
• Following these transactions, Caplan directly owns 153,544 shares of common stock and indirectly owns 358,806 shares through a trust and 118,810 shares through a family trust.
• Caplan also holds 17,924 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.

Industry Context

This is a routine filing for executive stock transactions and is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the healthcare and biotech sectors, such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The reported transactions are consistent with standard executive compensation practices, where stock options are granted as part of the overall package and are often exercised and sold for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they involve the sale of shares by a company executive.
• The use of a 10b5-1 plan provides transparency and reduces the risk of insider trading concerns.

Key Dates

Keywords

Form 4, insider trading, stock options, Rule 10b5-1, executive compensation, stock sales, Fractyl Health, GUTS